Kam-Ko Bio-Pharm v. Mayne Pharma

CourtCourt of Appeals for the Ninth Circuit
DecidedMarch 11, 2009
Docket07-35449
StatusPublished

This text of Kam-Ko Bio-Pharm v. Mayne Pharma (Kam-Ko Bio-Pharm v. Mayne Pharma) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kam-Ko Bio-Pharm v. Mayne Pharma, (9th Cir. 2009).

Opinion

FOR PUBLICATION UNITED STATES COURT OF APPEALS FOR THE NINTH CIRCUIT

KAM-KO BIO-PHARM TRADING CO.,  LTD-AUSTRALASIA, a Washington Corporation, Plaintiff-Appellant, v. MAYNE PHARMA (USA) INC., a No. 07-35449 Delaware corporation; MAYNE PHARMA PTY, LTD, an Australia  D.C. No. CV-06-00840-TSZ corporation (now known as Mayne OPINION Pharma Ltd.); MAYNE GROUP LTD, an Australian public company; DAVID BULL LABORATORIES, an Australian proprietary company; and John Does 1-12, Defendants-Appellees.  Appeal from the United States District Court for the Western District of Washington Thomas S. Zilly, District Judge, Presiding

Argued and Submitted January 22, 2009—Seattle, Washington

Filed March 11, 2009

Before: Robert R. Beezer, Richard C. Tallman, and Milan D. Smith, Jr., Circuit Judges.

Opinion by Judge Milan D. Smith, Jr.

3191 KAM-KO BIO-PHARM v. MAYNE PHARMA 3193

COUNSEL

Shaunta Marie Knibb & Jeff A. Smyth, Smyth & Mason, PLLC, Seattle, Washington for the plaintiff-appellant.

Alan S. Middleton, Davis Wright Tremaine LLP, Seattle, Washington for the defendants-appellees.

OPINION

MILAN D. SMITH, JR., Circuit Judge:

Plaintiff-Appellant Kam-Ko Bio-Pharm Trading Co., Ltd- Australasia (Kam-Ko) successfully sued Defendants- 3194 KAM-KO BIO-PHARM v. MAYNE PHARMA Appellees Mayne Pharma (USA) Inc. (Mayne) in district court to compel arbitration before the International Chamber of Commerce (ICC). A short time later, however, Kam-Ko filed a new lawsuit in district court seeking a declaration that the ICC’s $220,000 advance arbitration fee was so high as to be substantively unconscionable under the Federal Arbitration Act (FAA), 9 U.S.C. §§ 1-16, and Washington law. The dis- trict court rejected Kam-Ko’s argument and, when the parties failed to comply with its directive to proceed with arbitration within sixty days, dismissed Kam-Ko’s declaratory relief action with prejudice. Given the entirely commercial nature of this dispute, we affirm.

FACTUAL AND PROCEDURAL BACKGROUND

A. Royalty Agreement

Kam-Ko is a Washington company that assisted other com- panies in securing distribution deals in the Pacific Rim for anti-cancer drugs produced by NaPro BioTherapeutics, Inc. (NaPro). Kam-Ko provided its services to help Mayne’s alleged predecessor-in-interest obtain a distribution deal with NaPro in exchange for an agreement (Royalty Agreement) that required an up-front payment of $50,000 and a seventeen- year royalty equal to 5% of the bulk price paid to NaPro. Dur- ing contract negotiations, Kam-Ko proposed a process for dis- pute resolution, and its draft language was included, unaltered, as paragraph six of the Royalty Agreement:

Disputes. Any disputes will be settled by binding arbitration under an outside committee of three attor- neys acceptable to both parties, under terms of Inter- national Chamber of Commerce arbitration guidelines, in Vancouver, B.C., Canada, should such dispute not be resolved within 30 days between the parties. The losing party will pay the cost of such arbitration. KAM-KO BIO-PHARM v. MAYNE PHARMA 3195 B. Disputed Termination of Royalty Agreement and Kam-Ko’s Subsequent Action to Compel Arbitra- tion

In December 2003, Mayne informed Kam-Ko that the Roy- alty Agreement was terminated because Mayne had purchased NaPro and believed this acquisition relieved Mayne of any obligations to continue making payments. Kam-Ko replied that the purchase did not relieve Mayne of its obligation to pay, and that if the parties were unable to reach an agreement on the matter within thirty days, Kam-Ko would seek to com- pel arbitration under paragraph six of the Royalty Agreement. Mayne did not reply, and Kam-Ko filed suit in the district court to compel arbitration. Pursuant to a stipulated order, the district court ordered the dispute referred to the ICC for arbi- tration and dismissed the case without prejudice.

C. Proceedings Before the ICC

Kam-Ko filed a request for arbitration with the ICC in July 2005. Upon submission of the request, the ICC required Kam- Ko to pay a $2500 non-refundable deposit. The ICC then required a provisional advance from Kam-Ko of $45,000 with credit for the previously paid $2500. After some delay, Kam- Ko’s principals personally loaned the company the money to pay the balance due. The ICC confirmed the parties’ choices of one arbitrator each, appointed a third arbitrator to act as chairman of the tribunal, and set the advance costs at $220,000 to be split by Kam-Ko and Mayne, with credit to Kam-Ko for the amount it had previously paid.

Kam-Ko objected to the $220,000 amount as “confiscatory and punitive,” and as “wholly unforeseeable to the parties.” Mayne also objected to the amount, saying it “appears exces- sive and is unduly burdensome to both parties.” Neither party submitted further payment to the ICC. Under the ICC rules, for the arbitration to proceed, Kam-Ko, as the claimant, was required to pay the entire amount due, or some form of secur- 3196 KAM-KO BIO-PHARM v. MAYNE PHARMA ity in lieu of cash, if Mayne did not pay. After a number of extensions of payment deadlines, the ICC deemed the arbitra- tion withdrawn. The ICC fixed the costs already incurred in the arbitration at $40,053, deducted that amount from Kam- Ko’s payments of $45,000, and refunded $4947 to Kam-Ko.

D. Declaratory Relief Action

Kam-Ko then returned to the district court, seeking (1) “a declaration that the arbitration provision of the Royalty Agreement is illegal and unenforceable”; (2) “an order reforming the Royalty Agreement by severing the arbitration clause”; and (3) damages for Mayne’s alleged breach of the Royalty Agreement.

In a subsequent, self-styled “motion for declaratory judg- ment,” Kam-Ko requested a “speedy declaratory judgment hearing pursuant to Rule 57, Fed. R. Civ. P.,” and argued that the arbitration clause was substantively unconscionable because of the alleged unreasonable financial burden it placed on Kam-Ko as a precondition to arbitration. To support its position, Kam-Ko offered sworn testimony that it would be unable to pay the arbitration fee and proceed with its claims if the district court enforced the arbitration clause. Mayne responded by asserting that Kam-Ko’s motion was actually a motion for summary judgment because the motion sought to skip a hearing and obtain a merits ruling on the issue of unconscionability. Mayne also asked the district court to stay the action pending arbitration in accordance with the Royalty Agreement.

The district court denied Kam-Ko’s declaratory judgment motion without reference to the request for a hearing, finding that “the arbitration clause is not void for substantive uncons- cionability.” The district court also granted Mayne’s request for a stay and directed the parties to proceed to arbitration within sixty days of the order. When the parties failed to pro- ceed to arbitration as directed, the district court entered a stip- KAM-KO BIO-PHARM v. MAYNE PHARMA 3197 ulated order dismissing Kam-Ko’s declaratory judgment action with prejudice. Kam-Ko timely appealed.

STANDARD OF REVIEW AND JURISDICTION

The validity of an arbitration clause is a question that we review de novo. Nagrampa v. MailCoups, Inc., 469 F.3d 1257, 1267 (9th Cir. 2006) (en banc). Although Kam-Ko is correct that we review a district court’s denial of declaratory relief under Rule 57

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Green Tree Financial Corp.-Alabama v. Randolph
531 U.S. 79 (Supreme Court, 2000)
Principal Life Ins. Co. v. Robinson
394 F.3d 665 (Ninth Circuit, 2005)
In Re the Disciplinary Proceeding Against Greer
380 P.2d 482 (Washington Supreme Court, 1963)
Nelson v. McGoldrick
896 P.2d 1258 (Washington Supreme Court, 1995)
MA Mortenson Co. v. Timberline Software Corporation
998 P.2d 305 (Washington Supreme Court, 2000)
Pacific Indemnity Co. v. McDonald
107 F.2d 446 (Ninth Circuit, 1939)
Luna v. Household Finance Corp. III
236 F. Supp. 2d 1166 (W.D. Washington, 2002)
Zuver v. Airtouch Communications, Inc.
103 P.3d 753 (Washington Supreme Court, 2004)
Adler v. Fred Lind Manor
103 P.3d 773 (Washington Supreme Court, 2005)
In re the Disciplinary Proceeding Against Boelter
985 P.2d 328 (Washington Supreme Court, 1999)
In re the Arbitration between Teleserve Systems, Inc. & MCI Telecommunications Corp.
230 A.D.2d 585 (Appellate Division of the Supreme Court of New York, 1997)
Thompson v. Mahre
110 F.3d 716 (Ninth Circuit, 1997)

Cite This Page — Counsel Stack

Bluebook (online)
Kam-Ko Bio-Pharm v. Mayne Pharma, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kam-ko-bio-pharm-v-mayne-pharma-ca9-2009.